Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A prochelator activated by hydrogen peroxide prevents metal-induced amyloid Beta aggregation.

Literature DB >> 19937900

A prochelator activated by hydrogen peroxide prevents metal-induced amyloid Beta aggregation.

Marina G Dickens¹, Katherine J Franz.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 19937900 PMCID： PMC2863026 DOI： 10.1002/cbic.200900597

Source DB: PubMed Journal: Chembiochem ISSN： 1439-4227 Impact factor: 3.164

× No keyword cloud information.

36 in total

Review 1. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease.

Authors: Lauren E Scott; Chris Orvig
Journal: Chem Rev Date: 2009-10 Impact factor: 60.622

Review 2. The metallobiology of Alzheimer's disease.

Authors: Ashley I Bush
Journal: Trends Neurosci Date: 2003-04 Impact factor: 13.837

3. Toxicologic studies on borax and boric acid.

Authors: R J Weir; R S Fisher
Journal: Toxicol Appl Pharmacol Date: 1972-11 Impact factor: 4.219

Review 4. Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta.

Authors: Craig S Atwood; Mark E Obrenovich; Tianbing Liu; Hsien Chan; George Perry; Mark A Smith; Ralph N Martins
Journal: Brain Res Brain Res Rev Date: 2003-09

5. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.

Authors: X Huang; M P Cuajungco; C S Atwood; M A Hartshorn; J D Tyndall; G R Hanson; K C Stokes; M Leopold; G Multhaup; L E Goldstein; R C Scarpa; A J Saunders; J Lim; R D Moir; C Glabe; E F Bowden; C L Masters; D P Fairlie; R E Tanzi; A I Bush
Journal: J Biol Chem Date: 1999-12-24 Impact factor: 5.157

Review 6. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors: John Hardy; Dennis J Selkoe
Journal: Science Date: 2002-07-19 Impact factor: 47.728

7. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

Authors: Craig W Ritchie; Ashley I Bush; Andrew Mackinnon; Steve Macfarlane; Maree Mastwyk; Lachlan MacGregor; Lyn Kiers; Robert Cherny; Qiao-Xin Li; Amanda Tammer; Darryl Carrington; Christine Mavros; Irene Volitakis; Michel Xilinas; David Ames; Stephen Davis; Konrad Beyreuther; Rudolph E Tanzi; Colin L Masters
Journal: Arch Neurol Date: 2003-12

8. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage.

Authors: Kun Zou; Jian-Sheng Gong; Katsuhiko Yanagisawa; Makoto Michikawa
Journal: J Neurosci Date: 2002-06-15 Impact factor: 6.167

Review 9. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease.

Authors: Rudy J Castellani; Kazuhiro Honda; Xiongwei Zhu; Adam D Cash; Akihiko Nunomura; George Perry; Mark A Smith
Journal: Ageing Res Rev Date: 2004-07 Impact factor: 10.895

10. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).

Authors: Carlos Opazo; Xudong Huang; Robert A Cherny; Robert D Moir; Alex E Roher; Anthony R White; Roberto Cappai; Colin L Masters; Rudolph E Tanzi; Nibaldo C Inestrosa; Ashley I Bush
Journal: J Biol Chem Date: 2002-08-20 Impact factor: 5.157

23 in total

Review 1. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

Authors: Colin L Masters; Dennis J Selkoe
Journal: Cold Spring Harb Perspect Med Date: 2012-06 Impact factor: 6.915

2. A prochelator activated by beta-secretase inhibits Abeta aggregation and suppresses copper-induced reactive oxygen species formation.

Authors: Drew S Folk; Katherine J Franz
Journal: J Am Chem Soc Date: 2010-04-14 Impact factor: 15.419

A prochelator activated by hydrogen peroxide prevents metal-induced amyloid Beta aggregation.

Review 1. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease.

Review 2. The metallobiology of Alzheimer's disease.

3. Toxicologic studies on borax and boric acid.

Review 4. Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta.

5. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.

Review 6. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

7. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

8. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage.

Review 9. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease.

10. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).

Review 1. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

2. A prochelator activated by beta-secretase inhibits Abeta aggregation and suppresses copper-induced reactive oxygen species formation.

3. Development of bifunctional stilbene derivatives for targeting and modulating metal-amyloid-β species.

4. A Cell-Permeable Fluorescent Prochelator Responds to Hydrogen Peroxide and Metal Ions by Decreasing Fluorescence.

Review 5. Misfolded proteins in Alzheimer's disease and type II diabetes.

6. Prochelators triggered by hydrogen peroxide provide hexadentate iron coordination to impede oxidative stress.

7. Stimulus-Responsive Prochelators for Manipulating Cellular Metals.

8. Modifying aroylhydrazone prochelators for hydrolytic stability and improved cytoprotection against oxidative stress.

Review 9. Prodrug strategies for targeted therapy triggered by reactive oxygen species.

10. Exploiting innate immune cell activation of a copper-dependent antimicrobial agent during infection.